The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksMercia Asset Regulatory News (MERC)

Share Price Information for Mercia Asset (MERC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 32.70
Bid: 32.00
Ask: 33.40
Change: 0.00 (0.00%)
Spread: 1.40 (4.375%)
Open: 32.70
High: 32.70
Low: 32.70
Prev. Close: 32.70
MERC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Sale of Oxford Genetics Limited

1 Mar 2021 15:27

RNS Number : 7512Q
Mercia Asset Management PLC
01 March 2021
 

RNS

 1 March 2021

 

Mercia Asset Management PLC

 

("Mercia" the "Company" or the "Group")

 

Sale of Oxford Genetics Limited

 

Disposal delivers strategic objective of 'evergreening' Mercia's balance sheet

 

Mercia Asset Management PLC (AIM: MERC), the proactive, regionally focused specialist asset manager with c.£872million of assets under management, is pleased to announce the profitable sale of Oxford Genetics Limited ("Oxgene") to an international life sciences group.

 

Mercia held a 32.1% direct holding in Oxgene at the date of completion and will receive cash proceeds of £30.7million, its largest cash exit to date.

 

The sale results in a realised gain of £14.6million above Oxgene's £16.1million direct investment holding value as at 30 September 2020. The sale has generated a 5x return on Mercia's direct investment cost of £6.1million and a 51% internal rate of return ("IRR").

 

Mercia first invested in Oxgene in July 2013 through its third-party managed EIS funds and it subsequently became a direct investment in December 2015.

 

In addition to the direct investment return, the sale has generated returns of between 13x and 20x investment cost for five of Mercia's EIS funds, generating fund IRRs of between 38% and 49%. Mercia has proactively supported Oxgene since its beginning, including representation throughout on Oxgene's board by Mercia's Chief Executive Officer, Dr Mark Payton.

 

Dr Mark Payton, CEO of Mercia Asset Management PLC, said: "Oxgene is a great business and we are proud of the role Mercia has played, proactively supporting the team from its founding through to this landmark transaction, which will enable the business to continue its pioneering work. The sale of Mercia's shareholding in Oxgene demonstrates both the power of our regional networks and the strength of our unique Complete Connected Capital model. This exit therefore delivers an excellent result for Oxgene's founders and employees, our shareholders and our third-party EIS fund investors.

 

This event is also a significant milestone for Mercia as the exit proceeds now 'evergreen' our balance sheet; another of our key strategic objectives. The full cash sale of our second largest direct investment will enable the Group to support and expand its direct investment portfolio for the foreseeable future. We continue to believe that this diversified portfolio, in terms of sector and stage of development, offers further promise over the near to medium term.

 

Finally, this transaction reaffirms the significant opportunity and value creation potential offered by Mercia's 'funds first' hybrid investment model, focused on promising companies located outside of London and in what we term 'The Thriving Regions'."

 

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) 596/2014 which is part of UK law by virtue of the European Union (Withdrawal) Act 2018. Upon publication of this announcement, this inside information is now considered to be in the public domain.

 

-Ends-

 

For further information, please contact:

 

Mercia Asset Management PLC

Mark Payton, Chief Executive Officer

Martin Glanfield, Chief Financial Officer

www.mercia.co.uk

 

+44 (0)330 223 1430

 

Canaccord Genuity Limited (NOMAD and Joint Broker)

+44 (0)20 7523 8000

Simon Bridges, Emma Gabriel, Richard Andrews

N+1 Singer (Joint Broker)

Harry Gooden, James Moat

 

+44 (0)20 7496 3000

FTI Consulting 

+44 (0)20 3727 1051

Tom Blackwell, Louisa Feltes, Shiv Talwar

mercia@fticonsulting.com

 

About Mercia Asset Management PLC:

Mercia is a proactive, specialist asset manager focused on supporting regional SMEs to achieve their growth aspirations. Mercia provides capital across its four asset classes of balance sheet, venture, private equity and debt capital: the Group's 'Complete Connected Capital'. The Group initially nurtures businesses via its third-party funds under management, then over time Mercia can provide further funding to the most promising companies, by deploying direct investment follow-on capital from its own balance sheet.

 

The Group has a strong UK footprint through its regional offices, 19 university partnerships and extensive personal networks, providing it with access to high-quality deal flow. Mercia currently has c.£872million of assets under management and, since its IPO in December 2014, has invested c.£106million gross into its direct investment portfolio.

 

Mercia Asset Management PLC is quoted on AIM with the EPIC "MERC".

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DISSSIFIFEFSEED
Date   Source Headline
20th Dec 201910:29 amRNSResult of General Meeting
9th Dec 20192:05 pmRNSSecond Price Monitoring Extn
9th Dec 20192:00 pmRNSPrice Monitoring Extension
5th Dec 20197:00 amRNSPosting of documents and Notice of GM
3rd Dec 20193:46 pmRNSResult of Accelerated Bookbuild to raise £30.0m
3rd Dec 20199:05 amRNSSecond Price Monitoring Extn
3rd Dec 20199:00 amRNSPrice Monitoring Extension
3rd Dec 20197:01 amRNSProposed Acquisition & ABB to raise £30.0million
3rd Dec 20197:00 amRNSHalf Year Results
20th Nov 20197:00 amRNSnDreams makes significant commercial progress
14th Nov 20197:00 amRNSAppointment of Joint Broker
5th Nov 201911:02 amRNSNotification of Major Holdings
4th Nov 20194:49 pmRNSNotification of Major Holdings
1st Nov 20194:31 pmRNSNotification of Major Holdings
22nd Oct 20194:54 pmRNSNotification of Major Holdings
17th Oct 20191:59 pmRNSNotification of Major Holdings
16th Oct 20197:36 amRNSNotification of Major Holdings
25th Sep 20197:00 amRNSAnnouncement of significant contract for OXGENE
24th Sep 201911:02 amRNSResult of AGM
24th Sep 20197:00 amRNSAGM Statement
10th Sep 20197:00 amRNS£7.5million syndicated investment into Voxpopme
1st Aug 20197:00 amRNSGrant of Options
29th Jul 20192:24 pmRNSNotification of Major Holdings
26th Jul 20197:00 amRNSPublication of Annual Report
8th Jul 20197:00 amRNSPreliminary Results
5th Jul 201910:00 amRNSChange of Name
2nd Jul 20197:00 amRNSDirectorate Change
21st May 20197:00 amRNS£2.4million syndicated investment into Medherant
15th May 20197:00 amRNS£2.0million syndicated investment into Locate Bio
14th May 20197:06 amRNSConcepta PLC confirms first myLotus® pregnancies
2nd May 20197:00 amRNSNotice of Preliminary Results
11th Apr 20199:41 amRNSPDMR Dealing
10th Apr 20197:00 amRNSDirector/ PDMR Dealings
28th Mar 20197:00 amRNS£6.5m syndicated investment into Oxford Genetics
18th Mar 20194:23 pmRNSPDMR / Director Dealings
15th Mar 20191:19 pmRNSPDMR / Director Dealings
12th Mar 20197:06 amRNSPortfolio company Concepta secures partnership
28th Feb 20197:00 amRNSPortfolio company announces six licensing deals
20th Feb 20197:00 amRNSSoftware & the Internet Portfolio Update
5th Feb 20197:00 amRNSAppointment of NOMAD
3rd Dec 20187:00 amRNSHalf Year Results
31st Oct 20187:00 amRNSNotice of Results
29th Oct 20187:00 amRNSNew Direct Investment in W2 Global Data Solutions
18th Oct 20187:00 amRNSCapital Markets Day
16th Oct 20187:00 amRNSNew Emerging Star investment into Locate Bio
21st Sep 201810:47 amRNSResult of AGM
21st Sep 20187:00 amRNSAGM Statement
18th Sep 20187:00 amRNSAston EyeTech secures multi-million pound contract
13th Sep 20187:00 amRNSNotice of Capital Markets Day
29th Aug 20187:00 amRNSGrant of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.